Church of PeptidesSearch
The Measured Pilgrim
Zealand Pharma + Roche
Petrelintide (formerly ZP8396) is an investigational, long-acting amylin analogue being studied for weight management. It acts through amylin signaling, which helps regulate fullness. It is not a GLP-1 medicine and is not FDA-approved.
ZUPREME-2 randomized 220 adults with overweight or obesity and type 2 diabetes. At 28 weeks, the sponsor reported mean weight loss of 7.4–9.2% across petrelintide groups versus 2.0% with placebo, using the efficacy estimand. That analysis estimates effects under specified treatment-adherence assumptions; it is not a prediction for an individual patient. October 7 announcement.
Gastrointestinal events were the most frequently reported adverse events. Discontinuation due to those events was 1.9% with petrelintide versus 1.7% with placebo. This measures stopping treatment for one category of side effects; it does not mean that only 1.9% experienced side effects.
Comparing percentages from separate trials can mislead when participants, duration and analyses differ. Published full data and longer follow-up will help clarify the benefit–risk balance.
The headline belongs in the ledger; the missing pages belong beside it. Keep the study population, analysis and side effects attached whenever you share the weight-loss figure.
Zealand Pharma developed the candidate under the name ZP8396. The ZUPREME phase 2 program studied people with overweight or obesity in separate populations with and without type 2 diabetes. Zealand and Roche entered a development partnership in 2025. Development background.
The October 7, 2026 sponsor announcement states that the phase 3a ZUPREME-3, -4 and -5 program has begun and the first participants have started treatment. This dated update supersedes older pipeline wording that describes phase 3 as planned. Dated announcement.
The Measured Pilgrim brought a promising chart to the gate. “A beginning,” said Doctide. She opened a larger ledger. “Then let us keep measuring.”
This bold passage and the character portrait are invented fiction, not scientific or historical fact.No. It remains investigational. Phase 3 testing is not a promise of approval.
No. They are distinct amylin analogues with separate development programs. Read Cagrilintide’s record separately.
The October 9 Friday Gospel explains the announcement and its limits. This profile is the standing reference for the molecule.
Evidence and source review: October 10, 2026. Sponsor announcements are identified separately from published trial papers. Clinical development does not establish approval.
Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.
Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.
Join Subject One for six short chapters, from laboratory and animal studies to human trials and today’s evidence.
Read the Petrelintide journey →